Genfit (GNFT) announced it has given formal notice to the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares. The delisting is anticipated to be effective prior to the opening of trading on November 20. Pascal Prigent, CEO of GENFIT, commented: “With a strong financial foundation underpinned by the successful development and commercialization of elafibranor in PBC, the decision to delist from Nasdaq is an opportunity to streamline operations and focus resources. This move supports greater operational efficiency and is consistent with our current pipeline development stage. We remain fully committed to our Euronext listing and to upholding high standards of corporate governance and transparency.” Genfit’s ordinary shares will remain listed on the regulated market of Euronext Paris as its primary trading market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNFT:
